Andrew Orth
Vermögen: 24 Mio $ am 30.09.2026
Vermögen: 24 Mio $ am 30.09.2026
Mr. Andrew C.
Orth is a President, Chief Executive Officer & Director at City Therapeutics, Inc. He is on the Board of Directors at City Therapeutics, Inc. Mr. Orth was previously employed as a Chief Commercial Officer by Krystal Biotech, Inc. and a Senior Vice President & Head-US Busines by Alnylam Pharmaceuticals, Inc. He received his undergraduate degree from the University of Wisconsin and an MBA from Johnson Graduate School of Management.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
2,06 % | 19.10.2026 | 1.063.154 ( 2,06 % ) | 24 Mio $ | 30.09.2026 |
| Unternehmen | Position | Beginn |
|---|
| Unternehmen | Position | Ende |
|---|---|---|
| KRYSTAL BIOTECH, INC. | Corporate Officer/Principal | 02.08.2023 |
| BIOGEN INC. | Corporate Officer/Principal | 01.01.2016 |
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Biogen, Inc.
Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
University of Wisconsin
University of Wisconsin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Johnson Graduate School of Management
Johnson Graduate School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Krystal Biotech, Inc.
Krystal Biotech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops gene therapies to patients living with debilitating diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen